TrialJournal of the European Academy of Dermatology and Venereology : JEADV2019

Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumab.

Y Umezawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.